Mefenamic acid solid dispersions: impact of formulation composition on processing parameters, product properties and performance

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)


The objective of this study was to develop an immediate release (IR), crystalline solid dispersion (CSD) formulation of Mefenamic acid (MFA) by hot-melt-extrusion (HME) and assess the impact of drug loading on process parameters, product physico-chemical properties and product performance. An HME process to produce a range of MFA-Soluplus®-Sorbitol polymer matrix CSD formulations was developed based on rheological screening assays of physical mixtures (PM). The impact of drug loading on process parameters was compared to the impact of drug loading on the physico-chemical properties of formulations. Based on process and product data, three groupings of API drug loading were identified: sub-saturated, saturated, and supersaturated systems. CSD formulations were obtained for 20 - 50% (w/w) drug loading containing the stable polymorphic form I of MFA. CSD formulations predominantly improved the consistency of the product performance. An Amorphous Solid Dispersion (ASD) was obtained for 10% (w/w) drug loading, exhibiting faster drug release even at physiologically relevant pH. This study illustrates the impact of drug loading on process and product characteristics and how a better understanding of maximum API solubility in a given polymer system can improve targeted formulation development.
Original languageEnglish
Article number121505
Number of pages15
JournalInternational Journal of Pharmaceutics
Early online date10 Feb 2022
Publication statusPublished - 25 Mar 2022


  • extrusion
  • solid dosage forms
  • oral drug delivery
  • solid dispersion
  • dissolution
  • formulation

Cite this